{"id":"NCT02823145","sponsor":"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.","briefTitle":"An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome","officialTitle":"An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06-08","primaryCompletion":"2023-01-27","completion":"2023-01-27","firstPosted":"2016-07-06","resultsPosted":"2023-09-25","lastUpdate":"2025-07-14"},"enrollment":375,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Dravet Syndrome"],"interventions":[{"type":"DRUG","name":"ZX008 (Fenfluramine Hydrochloride)","otherNames":[]}],"arms":[{"label":"ZX008","type":"EXPERIMENTAL"}],"summary":"This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome.","primaryOutcome":{"measure":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Open-label Extension (OLE) Treatment Period","timeFrame":"From Day 1 to End of OLE Treatment Period - End of Study (EOS) Visit (Month 42)","effectByArm":[{"arm":"Any ZX008 Open Label Dose","deltaMin":98.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":67,"countries":["United States","Australia","Belgium","Canada","Denmark","France","Germany","Italy","Japan","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["40072476","34768178"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":99,"n":374},"commonTop":["Pyrexia","Nasopharyngitis","Decreased appetite","Blood glucose decreased","Diarrhoea"]}}